Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8995939 | 0.92 | TGM2 (0.59) | TGM2LMNASMN1; SMN2NPC1KMT2A | |
| SCHEMBL732934 | 0.90 | TGM2 (0.81) | TGM2LMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL7784363 | 0.87 | ALDH1A1 (0.54) | TGM2LMNAKMT2AALDH1A1MAPT | |
| SCHEMBL7143585 | 0.83 | KMT2A (0.56) | TGM2LMNASMN1; SMN2NPC1KMT2A | |
| SCHEMBL3824015 | 0.83 | LMNA (0.66) | LMNASMN1; SMN2KMT2AALDH1A1HPGD | |
| SCHEMBL395033 | 0.83 | LMNA (0.66) | LMNASMN1; SMN2KMT2AALDH1A1HPGD | |
| SCHEMBL124217 | 0.83 | TGM2 (0.71) | TGM2LMNAALDH1A1 | |
| SCHEMBL2452377 | 0.83 | TGM2 (0.71) | TGM2LMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL20662744 | 0.83 | LMNA (0.67) | LMNASMN1; SMN2NPC1KMT2AALDH1A1 | |
| SCHEMBL19034703 | 0.82 | NPC1 (0.55) | TGM2LMNASMN1; SMN2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250389633-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-12-25 | — | — | US | claimed |
| US-20250298042-A1 | ENGINEERED PARTICLES AS RED BLOOD CELL MIMICS AND COMPOSITIONS CONTAINING SAME FOR HEMATOLOGY | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-09-25 | — | — | US | claimed |
| EP-4608872-A2 | SIZE-TUNABLE SYNTHETIC PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME FOR IMMUNE CELL ACTIVATION | Slingshot Biosciences, Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-12379387-B2 | Engineered particles as red blood cell mimics and compositions containing same for hematology | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-08-05 | — | — | US | claimed |
| EP-3256850-B1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES INC (US) | 2025-07-09 | — | — | EP | claimed |
| US-12352679-B2 | Synthetic human cell mimic particle for cytometric or coulter device | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | claimed |
| EP-4577823-A2 | COMPOSITIONS AND METHODS FOR SINGLE WELL MULTIPLEXED CALIBRATION AND COMPENSATION | Slingshot Biosciences, Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| US-20250189428-A1 | COMPOSITIONS AND METHODS FOR SINGLE WELL MULTIPLEXED CALIBRATION AND COMPENSATION | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-06-12 | — | — | US | claimed |
| US-20250164373-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | SLINGSHOT BIOSCIENCES, INC. (US) | 2025-05-22 | — | — | US | claimed |
| CN-119907921-A | Engineered particles as red blood cell mimics for hematology and compositions containing the same | 弹弓生物科学公司 | 2025-04-29 | — | — | CN | claimed |
| US-20220364976-A1 | COMPOSITIONS AND METHODS FOR CELL-LIKE CALIBRATION PARTICLES | SLINGSHOT BIOSCIENCES, INC. (US) | 2022-11-17 | — | — | US | claimed |
| CN-111138595-B | Water-based glazing oil emulsion with heat resistance, preparation method thereof and water-based glazing oil | 广东银洋环保新材料有限公司 | 2022-11-15 | — | — | CN | claimed |
| US-20220260476-A1 | HYDROGEL PARTICLES WITH TUNABLE OPTICAL PROPERTIES AND METHODS FOR USING THE SAME | SLINGSHOT BIOSCIENCES, INC. (US) | 2022-08-18 | — | — | US | claimed |
| US-6673886-B2 | FOR INTRAOCULAR LENSES | BAUSCH & LOMB INCORPORATED | 2004-01-06 | — | — | US | claimed |
| US-20020049290-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-25 | — | — | US | claimed |
| US-20020042483-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-11 | — | — | US | claimed |
| US-20020042484-A1 | High refractive index hydrogel compositions for ophthalmic implants | BAUSCH & LOMB MEXICO, S.A. DE C.V. (MX) | 2002-04-11 | — | — | US | claimed |
| US-20020037984-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-03-28 | — | — | US | claimed |
| US-6329485-B1 | FOR INTRAOCULAR LENSES | BAUSCH & LOMB INCORPORATED | 2001-12-11 | — | — | US | claimed |
| WO-2000034804-A1 | HIGH REFRACTIVE INDEX HYDROGEL COMPOSITIONS FOR OPHTHALMIC IMPLANTS | BAUSCH & LOMB SURGICAL, INC. (US) | 2000-06-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250389633-A1 | SYNTHETIC HUMAN CELL MIMIC PARTICLE FOR CYTOMETRIC OR COULTER DEVICE | CD4, ICOS, CD69 | TGM2 1495/4885LMNA 3949/4885SMN1; SMN2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.